DalCor Keeps Faith In CETP Biomarker, Despite No Dice For Merck's REVEAL Genetic Analysis

Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.

Cholesteryl ester transfer protein (3d structure) with a potential use in atherosclerosis therapy. It facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. - Illustration
Three-dimensional illustration of cholesteryl ester transfer protein (CETP), which facilitates the transport of cholesteryl esters and triglycerides between lipoproteins.

DalCor Pharmaceuticals says it's still confident about its dal-GenE outcomes study of genetically selected patients treated with the cholesterol-modulating CETP inhibitor dalcetrapib, but the odds on its big gamble are arguably worsening after a new analysis of Merck & Co. Inc.'s REVEAL outcomes study of anacetrapib did not support the hypothesis.

A retrospective analysis of data from Merck's massive REVEAL outcomes study of its CETP inhibitor anacetrapib, presented at the American College of Cardiology (ACC) annual meeting on March 18, did not show a trend for a benefit

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows more promise in slowing idiopathic pulmonary fibrosis.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

Boehringer’s Next Generation IPF Drug Underwhelms

 

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

More from R&D

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By 

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.